132 related articles for article (PubMed ID: 25817046)
1. Pazopanib can preserve cosmetic quality of life even in end-stage angiosarcoma.
Kitamura S; Hata H; Imafuku K; Haga N; Homma E; Shimizu H
Clin Exp Dermatol; 2015 Dec; 40(8):931-3. PubMed ID: 25817046
[No Abstract] [Full Text] [Related]
2. Angiosarcoma of the scalp successfully treated with pazopanib.
Tomita H; Koike Y; Asai M; Ogawa F; Abe K; Tanioka M; Utani A
J Am Acad Dermatol; 2014 Jan; 70(1):e19-21. PubMed ID: 24176520
[No Abstract] [Full Text] [Related]
3. Pazopanib: an alternative in taxane-resistant cutaneous angiosarcoma.
Fujita M; Endo Y; Fujisawa A; Tanioka M; Kabashima K; Miyachi Y
Eur J Dermatol; 2014; 24(2):267-8. PubMed ID: 24682601
[No Abstract] [Full Text] [Related]
4. Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors.
Tamiya H; Kamo R; Kumei A; Yanagihara S; Ishii M; Kobayashi H
Clin Exp Dermatol; 2012 Oct; 37(7):749-52. PubMed ID: 22369131
[TBL] [Abstract][Full Text] [Related]
5. Paradoxical antitumor effects of pazopanib in a cutaneous angiosarcoma patient.
Hoashi T; Hirabayashi M; Nakajima R; Takahashi N; Saeki H
J Dermatol; 2017 Sep; 44(9):1078-1079. PubMed ID: 27726177
[No Abstract] [Full Text] [Related]
6. Unresectable angiosarcoma treated with bevacizumab and paclitaxel.
Nespereira-Jato MV; Peña-Panabad C; Quindós-Varela M; García-Silva J
Actas Dermosifiliogr; 2014 Jun; 105(5):520-2. PubMed ID: 24144236
[No Abstract] [Full Text] [Related]
7. Low-dose administration of oral pazopanib for the treatment of recurrent angiosarcoma.
Miura H; Shirai H
Clin Exp Dermatol; 2015 Jul; 40(5):575-7. PubMed ID: 25753734
[No Abstract] [Full Text] [Related]
8. Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma.
Ogata D; Yanagisawa H; Suzuki K; Oashi K; Yamazaki N; Tsuchida T
Med Oncol; 2016 Oct; 33(10):116. PubMed ID: 27613162
[TBL] [Abstract][Full Text] [Related]
9. Angiosarcoma of the scalp successfully treated with a single therapy of sorafenib.
Ono S; Tanioka M; Fujisawa A; Tanizaki H; Miyachi Y; Matsumura Y
Arch Dermatol; 2012 Jun; 148(6):683-5. PubMed ID: 22710450
[No Abstract] [Full Text] [Related]
10. Liposomal doxorubicin in the treatment of metastasized angiosarcoma.
Waldmann V
Br J Dermatol; 2003 Mar; 148(3):606. PubMed ID: 12653770
[No Abstract] [Full Text] [Related]
11. Angiosarcoma of the scalp treated with OK-432 and rIL-2.
Miura H; Inui S; Sakai H; Hasebe N; Itami S; Yoshikawa K
Int J Dermatol; 2002 May; 41(5):286-8. PubMed ID: 12100706
[No Abstract] [Full Text] [Related]
12. Complete long-term response of angiosarcoma of the scalp with cervical lymph node metastases treated with a combination of weekly and monthly docetaxel.
Nakamura Y; Nakamura Y; Hori E; Furuta J; Kawachi Y; Otsuka F
Br J Dermatol; 2010 Dec; 163(6):1357-8. PubMed ID: 20731655
[No Abstract] [Full Text] [Related]
13. Complete remission of treatment-refractory advanced angiosarcoma of the scalp by protracted intralesional interleukin-2 therapy.
Gebhardt C; Ziegler B; Stadler S; Goerdt S; Utikal J
Br J Dermatol; 2015 Apr; 172(4):1156-8. PubMed ID: 25204400
[No Abstract] [Full Text] [Related]
14. A case of cutaneous angiosarcoma successfully treated with eribulin.
Iwamoto K; Fujisawa Y; Ishitsuka Y; Maruyama H; Nakamura Y; Okiyama N; Watanabe R; Fujimoto M
Eur J Dermatol; 2018 Jun; 28(3):410-412. PubMed ID: 29619993
[No Abstract] [Full Text] [Related]
15. A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol).
Oashi K; Shibata T; Namikawa K; Takahashi A; Yokota K; Nakano E; Teramoto Y; Tsutsumida A; Maeda T; Yamazaki N;
BMC Cancer; 2020 Jul; 20(1):652. PubMed ID: 32660439
[TBL] [Abstract][Full Text] [Related]
16. Pazopanib does not bring remarkable improvement in patients with angiosarcoma.
Kitamura S; Yanagi T; Inamura Y; Hata H; Imafuku K; Yoshino K; Shimizu H
J Dermatol; 2017 Jan; 44(1):64-67. PubMed ID: 27569550
[TBL] [Abstract][Full Text] [Related]
17. Pazopanib-Associated Transient Ischemic Attack.
Revuelta-Herrero JL; Escudero-Vilaplana V; Álvarez-Álvarez R; Sanjurjo-Sáez M
Am J Ther; 2018; 25(3):e393-e394. PubMed ID: 29424756
[No Abstract] [Full Text] [Related]
18. Combined nab-paclitaxel and irradiation for large cutaneous angiosarcoma of the face and scalp with pulmonary metastases.
André F; Frischhut N; Walder A; Skvortsov S; Schmuth M; Nguyen VA
J Dtsch Dermatol Ges; 2020 Jul; 18(7):754-757. PubMed ID: 32469459
[No Abstract] [Full Text] [Related]
19. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
Kollár A; Jones RL; Stacchiotti S; Gelderblom H; Guida M; Grignani G; Steeghs N; Safwat A; Katz D; Duffaud F; Sleijfer S; van der Graaf WT; Touati N; Litière S; Marreaud S; Gronchi A; Kasper B
Acta Oncol; 2017 Jan; 56(1):88-92. PubMed ID: 27838944
[TBL] [Abstract][Full Text] [Related]
20. Long-term metronomic docetaxel chemotherapy for inoperative angiosarcoma of the scalp.
Sumikawa Y; Inui S; Nishimura Y; Morita E; Kurachi K
J Dermatol; 2011 Apr; 38(4):393-5. PubMed ID: 21352341
[No Abstract] [Full Text] [Related]
[Next] [New Search]
